FIELD : medicine.SUBSTANCE : invention relates to the field of medicine, namely to ophthalmology, and is intended to determine indications for the treatment of primary open-angle glaucoma with the help of the brain-derived neurotrophic factor (BDNF). To determine the indications for the treatment of primary open-angle glaucoma with the help of BDNF in the lachrymal fluid (LF) of the patient, the concentration of BDNF is determined by the method of non-competitive enzyme immunoassay (EIA). When the concentration of BDNF in LF is less than 63?picograms/ml (pg/ml), its administration is shown.EFFECT : use of the invention provides for the determination of indications for the treatment of primary open-angle glaucoma with the help of BDNF.4 cl, 4 ex